Remove Bioinformatics Remove DNA Remove Protein Remove Scientist
article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

Its proprietary technology, Proximity Extension Assay (PEA), provides high throughput protein analysis. Through the purchase, Thermo Fisher will also gain a library of more than 5,300 validated protein biomarker targets. BioCina will provide process development and GMP manufacturing for Minicircle DNA and Plasmid DNA.

Drugs 52
article thumbnail

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Big data – charting a new path to drug discovery and development

Drug Discovery World

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59
article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’.

article thumbnail

Democratising proteomics for cancer and beyond

Drug Discovery World

DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick , about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. These mutated proteins then reprogramme the epigenome, from which the cancer develops.

Protein 52
article thumbnail

Could elephant genes hold the key to avoiding cancers?

Drug Discovery World

Scientists modelling the cancer-suppressing p53 gene identify how the 20 different molecules unique to elephants get activated for increased sensitivity and response against carcinogenic conditions – with implications for cancer treatments in humans.

Gene 52